Latest Breaking News On - Standard regimens - Page 1 : comparemela.com

The approval expands the prior indication of idecabtagene vicleucel (Abecma; Bristol Myers Squibb), which will make the drug available to patients in earlier lines.

United kingdomGreat britainBryan campbellBristol myers squibbAl olaa abdallahUs myeloma innovations research collaborativeUniversity of kansasEuropean unionCell therapySafety studyStandard regimensSubjects with relapsedRefractory multiple myelomaClinical associate professorClinical directorHematologic malignancies